Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01072357 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
A Phase 1 study of Corneal Neovascularization and Corneal Graft Failure, sponsored by Reza Dana, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01072357 is a Phase 1 study of Corneal Neovascularization and Corneal Graft Failure that has completed, run by Reza Dana, MD. The registered enrollment target is 30 participants, below the 72-participant average among 3 other Corneal Neovascularization trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01072357, a Phase 1 study of Corneal Neovascularization and Corneal Graft Failure, has completed, sponsored by Reza Dana, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The leading risk factor for corneal transplant rejection is abnormal blood vessel growth of the host bed. Vascular endothelial growth factor (VEGF) is thought to be a mediator of this corneal neovascularization (NV), therefore we would like to test the safety and efficacy of local VEGF blockade in the promotion of graft survival in high risk corneal transplants.
Conditions Studied
Interventions
- DRUG Avastin® (bevacizumab)
- DRUG 0.9% NaCl & Refresh Liquigel
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-12 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01072357
The ClinicalTrials.gov registry entry for NCT01072357 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 72-participant average among 3 other Corneal Neovascularization trials with a reported enrollment target (58% lower). The listed sponsor is Reza Dana, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Corneal Neovascularization appearing as the primary indexed condition, and to 2 interventions - of which Avastin® (bevacizumab) is the first listed.
NCT01072357 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01072357 about?
NCT01072357 is a clinical study titled "Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival". The leading risk factor for corneal transplant rejection is abnormal blood vessel growth of the host bed. Vascular endothelial growth factor (VEGF) is thought to be a mediator of this corneal neovascularization (NV), therefore we would like to test the safety and efficacy of local VEGF blockade in t...
What is the current status of trial NCT01072357?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2009-12. Estimated completion is 2015-01.
What conditions does trial NCT01072357 study?
This clinical trial studies the following conditions: Corneal Neovascularization, Corneal Graft Failure.
What interventions are being tested in trial NCT01072357?
The interventions under investigation include: Avastin® (bevacizumab) (DRUG), 0.9% NaCl & Refresh Liquigel (DRUG).
Who is sponsoring clinical trial NCT01072357?
This trial is sponsored by Reza Dana, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01072357 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corneal Neovascularization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
COMPLETED · Phase 1
-
Corneal Crosslinking for Treatment of Corneal Neovascularization
RECRUITING · Phase 2
-
Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.